Enhancing Cooperation Between Academic Biobanks and Biomedical Industry: Better Mutual Understanding and New Collaborative Models Are Needed

Puchois P , Miranda LB , Van Gool A . Introduction: The cardinal role of biobanks and human biospecimen collections in biomarker validation: Issues impeding impact of biomarker research outcomes. Comprehensive biomarker discovery and validation for clinical application. R Soc Chem, 2013; 33:73–110.

Chadwick D , Roehrl M . High-quality biobanking for personalized precision medicine: BioSpecimen Sciences at the helm. Diagn Histopathol (Oxf), 2013; 19:447–456.

Hofman P , Brechot C , Zatloukal K , Dagher G , Clement B . Public-private relationships in biobanking: A still underestimated key component of open innovation. Virchows Arch, 2014; 464:3–9.

Mackenzie F. Biobanking trends, challenges, and opportunities. Pathobiology, 2014; 81:245–251.

Simeon-Dubach D , Watson P . Biobanking 3.0: Evidence based and customer focused biobanking. Clin Biochem, 2014; 47:300–308.

Simeon-Dubach D , Henderson MK . Sustainability in biobanking. Biopreserv Biobank, 2014; 12:287–291.

D'Hooghe T. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health. Hum Reprod, 2017; 32:1549–1555.

Wang HR. “Publish or perish”: Should this still be true for your data?. Data Brief, 2014; 1:85–86.

Allen L , Scott J , Brand A , Hlava M , Altman M . Publishing: Credit where credit is due. Nature, 2014; 508:312–313.

Ellinger B , Gribbon P . Risk mitigation in academic drug discovery. Expert Opin Drug Discov, 2016; 11:333–336.

Kern SE. Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures. Cancer Res, 2012; 72:6097–6101.

Barker AD , Compton CC , Poste G . The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic. Biomark Med, 2014; 8:873–876.

Vallance P , Williams P , Dollery C . The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin Pharmacol Ther, 2010; 87:525–527.

Schachter B. Partnering with the professor. Nat Biotechnol, 2012; 30:944–952.

Schuhmacher A , Gassmann O , Hinder M . Changing R&D models in research-based pharmaceutical companies. J Transl Med, 2016; 14:105.

Mullard A. Parsing clinical success rates. Nat Rev Drug Discov, 2016; 15:447.

Matzke EAM , O'Donoghue S , Barnes RO , et al. Certification for biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank, 2012; 10:426–432.

Tumilasci V. Taking out the “Bank” out of biobank. Pathologist, 2017; 36:16–17.

Puchois P. Finding ways to improve the use of biobanks. Nat Med, 2013; 19:814–815.

Cambon-Thomsen A , Thorisson GA , Mabile L . The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Genet, 2011; 43:503–504.

Howard HC , Mascalzoni D , Mabile L , Houeland G , Rial-Sebbag E , Cambon-Thomsen A . How to responsibly acknowledge research work in the era of big data and biobanks: Ethical aspects of the Bioresource Research Impact Factor (BRIF). J Commun Genet, 2018; 9:169–176.

van Gool AJ , Bietrix F , Caldenhoven E , et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov, 2017; 16:587–588.

Compton C. Garbage-in, garbage-out. Pathologist, 2018; 40:19–27.

Andry C , Duffy E , Moskaluk CA , McCall S , Roehrl MHA , Remick D . Biobanking-budgets and the role of pathology biobanks in precision medicine. Acad Pathol, 2017; 4:2374289517702924.

Fitzgibbons PL , Bradley LA , Fatheree LA , et al. Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med, 2014; 138:1432–1443.

Cavallo J , Simeon-Dubach D , Allen D. Challanges for industry working with academic biobanks:survey supported by the ISBER Pharma Working Group. ISBER Conference, Berlin; 2016. https://trans-hit.com/static/upload/pdf/isber-working-group-berlin-2016.pdf

Paradiso AV , Daidone MG , Canzonieri V , Zito A . Biobanks and scientists: Supply and demand. J Transl Med, 2018; 16:136.

Warner TD , Weil CJ , Andry C , et al. Broad consent for research on biospecimens: The views of actual donors at four U.S. medical centers. J Empir Res Hum Res Ethics, 2018; 13:115–124.

LaBaer J , Miceli JF III , Freedman LP . What's in a sample? Increasing transparency in biospecimen procurement methods. Nat Methods, 2018; 15:303–304.

Cooreman A , Bravo E , Van Gool A , Puchois P , Roehrl MH , Hofman P. Point of view: Traceability and transparency should be mandatory for all human biospecimens. Appl Clin Trials, May 8, 2017. http://www.appliedclinicaltrialsonline.com/point-view-traceability-and-transparency-should-be-mandatory-all-human-biospecimens?pageID=2

Washetine K , Heeke S , Bonnetaud C , et al. Establishing a dedicated lung cancer biobank at the University Center Hospital of Nice (France). Why and How? Cancers (Basel), 2018; 10:E220.

Avery D. Biobanking consent: Informing human subjects of the possibilities. Biobanking.com; July 16, 2018. https://www.biobanking.com/biobanking-consent-informing-human-subjects-of-the-possibilities/

Spector-Bagdady K , De Vries RG , Gornick MG , Shuman AG , Kardia S , Platt J . Encouraging participation and transparency in biobank research. Health Aff (Millwood), 2018; 37:1313–1320.

Hofman V , Ilie M , Long E , et al. Measuring the contribution of tumor biobanks to research in oncology: Surrogate indicators and bibliographic output. Biopreserv Biobank, 2013; 11:235–244.

Lee JE. How should biobanks collect biosamples for clinical application? A 20-year biomarker-related publication and patent trend analysis. Osong Public Health Res Perspect, 2018; 9:105–111.

Hewitt R , Tumilasci V , Cooreman A. Can collaboration with industry make academic biobanks sustainable? If so, what do they have to change to work with industry? Europ Biobank Week, Antwerp, Belgium; September 5, 2018.